Elevation Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Elevation Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.82K	Hold	47	–	–	﹤0.01%	1201
2026 Q2	$2.69K	Sell	47 -353	-88%	-$19.3K	﹤0.01%	1150
2026 Q1	$22.6K	Hold	400	–	–	0.01%	353
2025 Q4	$23.8K	Buy	400 +397	+13,233%	+$21.6K	0.01%	334
2025 Q3	$163	Hold	3	–	–	﹤0.01%	854
2025 Q2	$165	Hold	3	–	–	﹤0.01%	460
2025 Q1	$213	Hold	3	–	–	﹤0.01%	462
2024 Q4	$198	Hold	3	–	–	﹤0.01%	467
2024 Q3	$211	Hold	3	–	–	﹤0.01%	450
2024 Q2	$247	Hold	3	–	–	﹤0.01%	477
2024 Q1	$263	Hold	3	–	–	﹤0.01%	444
2023 Q4	$266	Hold	3	–	–	﹤0.01%	416
2023 Q3	$266	Hold	3	–	–	﹤0.01%	315
2023 Q2	$261	Hold	3	–	–	﹤0.01%	327
2023 Q1	$292	Buy	+3	New	+$311	﹤0.01%	327

Other funds holding BMRN

FFBTD

First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MGI

Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

WPC

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Elevation Wealth Partners's BMRN Position: Q3 2026 in Review

Elevation Wealth Partners held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 47 shares worth $2.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

Elevation Wealth Partners first reported a position in BMRN in Q1 2023 and has held it in 15 quarters since. The position peaked at $23.8K in Q4 2025. 17 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Elevation Wealth Partners held 47 shares of BioMarin Pharmaceuticals worth $2.82K as of Q3 2026.
Elevation Wealth Partners left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #1201 holding.
Elevation Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q1 2023 and has held it in 15 quarters since.
Elevation Wealth Partners's BioMarin Pharmaceuticals position peaked at $23.8K in Q4 2025.
17 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.